Suchergebnisse - "Stutters, Jonathan"

PubPharm (16)

1

Repurposing Clinical MRI Archives for Multiple Sclerosis Research with a Flexible, Single-Modality Approach: New Insights from Old Scans

enthalten in: bioRxiv.org | 2024

von Goebl, P. | Wingrove, J. | Abdelmannan, O. | +19

2

Networks of microstructural damage predict disability in multiple sclerosis

enthalten in: Journal of neurology, neurosurgery, and psychiatry | 2023

von Colato, E. | Prados, F. | Stutters, J. | +8

3

Longitudinal Metabolite Changes in Progressive Multiple Sclerosis : A Study of 3 Potential Neuroprotective Treatments

enthalten in: Journal of magnetic resonance imaging : JMRI | 2023

von John, N. | Solanky, B. | De Angelis, F. | +16

4

Remyelination varies between and within lesions in multiple sclerosis following bexarotene

enthalten in: Annals of clinical and translational neurology | 2022

von Brown, J. | Prados, F. | Altmann, D. | +15

5

Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis

enthalten in: Neurology | 2022

von Calvi, A. | Carrasco, F. | Tur, C. | +13

CommentIn: Neurology. 2022 Apr 26;98(17):699-700. - PMID 35277445

6

Efficacy and safety of temelimab in multiple sclerosis : Results of a randomized phase 2b and extension study

enthalten in: Multiple sclerosis (Houndmills, Basingstoke, England) | 2022

von Hartung, H. | Derfuss, T. | Cree, B. | +18

7

Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis

enthalten in: NeuroImage. Clinical | 2022

von Calvi, A. | Tur, C. | Chard, D. | +11

8

Remyelination varies between and within lesions in multiple sclerosis following bexarotene

enthalten in: Annals of Clinical and Translational Neurology | 2022

von Brown, J. | Prados, F. | Altmann, D. | +15

9

Predicting disability progression and cognitive worsening in multiple sclerosis using grey matter network measures

enthalten in: bioRxiv.org | 2021

von Colato, E. | Stutters, J. | Tur, C. | +7

10

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One) : a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study

enthalten in: The Lancet. Neurology | 2021

von Brown, J. | Cunniffe, N. | Prados, F. | +21

CommentIn: Lancet Neurol. 2021 Sep;20(9):686-687. - PMID 34418383